Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats

Inflammation

Volumn 37, Issue 3, 2014, Pages 924-932

  Luan, Zheng Gang ^a   Naranpurev, Mendsaikhan ^b   Ma, Xiao Chun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Department of Intensive Care Unit State Central Hospital of Mongolia   (Mongolia)

Author keywords

acute lung injury; inflammation; low molecular weight heparin; survival

Indexed keywords

DALTEPARIN; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE; PEROXIDASE; STREPTAVIDIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HBP1 PROTEIN, RAT; IL1B PROTEIN, RAT; RELA PROTEIN, RAT; TRANSCRIPTION FACTOR RELA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOW DRUG DOSE; LUNG EDEMA; LUNG FLUID; MALE; MORTALITY; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SURVIVAL; ACTIVE TRANSPORT; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; EDEMA; ENDOTOXEMIA; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; RANDOMIZATION; WISTAR RAT;

RATTUS;

ACTIVE TRANSPORT, CELL NUCLEUS; ACUTE LUNG INJURY; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; EDEMA; ENDOTOXEMIA; ENDOTOXINS; HEPARIN, LOW-MOLECULAR-WEIGHT; HMGB1 PROTEIN; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; LUNG; MALE; NEUTROPHILS; NF-KAPPA B P50 SUBUNIT; PEROXIDASE; RANDOM ALLOCATION; RATS; RATS, WISTAR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902549849     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9812-6     Document Type: Article

References (47)

1. Dreyfuss, D., and G. Saumon. 1998. Ventilator-induced lung injury: lessons from experimental studies. American Journal of Respiratory and Critical Care Medicine 157: 294-323. (Pubitemid 28071297)
2. Ware, L.B., and M.A. Matthay. 2000. The acute respiratory distress syndrome. New England Journal of Medicine 342: 1334-1349. (Pubitemid 30408719)
3. Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. Journal of Pathology 202: 145-156. (Pubitemid 38208651)
4. Ghosh, S., R.D. Latimer, B.M. Gray, et al. 1993. Endotoxin-induced organ injury. Critical Care Medicine 21: S19-S24. (Pubitemid 23057709)
5. Xu, H., X. Ye, H. Steinberg, et al. 2010. Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. Journal of Pathology 220: 490-498.
6. Bustin, M. 1999. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Molecular and Cellular Biology 19: 5237-5246. (Pubitemid 29339883)
7. Wang, H.,O. Bloom, M. Zhang, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251. (Pubitemid 29329996)
8. Reiss, L.K., U. Uhlig, and S. Uhlig. 2012. Models and mechanisms of acute lung injury caused by direct insults. European Journal of Cell Biology 91: 590-601.
9. Kim, J.Y., J.S. Park, D. Strassheim, et al. 2005. HMGB1 contributes to the development of acute lung injury after hemorrhage. American Journal of Physiology - Lung Cellular and Molecular Physiology 288: L958-L965. (Pubitemid 40547924)
10. Scaffidi, P., T. Misteli, and M.E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195. (Pubitemid 34773774)
11. Andersson, U., H. Wang, K. Palmblad, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 192: 565-570. (Pubitemid 30666257)
12. Barsness, K.A., J. Arcaroli, A.H. Harken, et al. 2004. Hemorrhage-induced acute lung injury is TLR-4 dependent. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 287: R592-R599. (Pubitemid 39095934)
13. Xie, K., Y. Yu, Y. Huang, et al. 2012. Molecular hydrogen ameliorates lipopolysaccharide-induced acute lung injury in mice through reducing inflammation and apoptosis. Shock 37: 548-555.
14. Gong, Q., J.F. Xu, H. Yin, et al. 2009. Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scandinavian Journal of Immunology 69: 29-35.
15. Wang, H., J.M. Vishnubhakat, O. Bloom, et al. 1999. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392. (Pubitemid 29382808)
16. Fiuza, C., M. Bustin, S. Talwar, et al. 2003. Inflammation-promoting activity of HMGB1 on human micro vascular endothelial cells. Blood 101: 2652-2660. (Pubitemid 36857626)
17. Park, J.S., F. Gamboni-Robertson, Q. He, et al. 2006. High Mobility Group Box 1 protein (HMGB1) interacts with multiple toll like receptors. American Journal of Physiology-Cellular Physiology 290: 917-924.
18. Kokkola, R., A. Andersson, G. Mullins, et al. 2005. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scandinavian Journal of Immunology 61: 1-9. (Pubitemid 40188342)
19. Iba, T., A. Kidokoro, and Y. Yagi. 1998. The role of the endotheliumin changes in procoagulant activity. Journal of the American College of Surgeons 87: 321-329. (Pubitemid 28433441)
20. Macfarlane, S.R., M.J. Seatter, T. Kanke, et al. 2001. Proteinase-activated receptors. Pharmacological Reviews 53: 245-282. (Pubitemid 32476117)
21. Freeman, B.D., B.A. Zehnbauer, and T.G. Buchman. 2003. A metaanalysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20: 5-9.
22. Matthay, M.A. 2001. Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. New England Journal of Medicine 344: 759-762.
23. Al-Ansari, E., H.K. Du, L. Yu, et al. 2007. Low molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs. Chest 132: 1898-1905.
24. Li, L.F., C.C. Huang, H.C. Lin, et al. 2009. Unfractionated heparin and enoxaparin reduce high stretch ventilation-augmented lung injury-a prospective, controlled animal experiment. Critical Care 13: R108.
25. Darien, B.J., J. Fareed, K.S. Centgraf, et al. 1998. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 9: 274-281. (Pubitemid 128463295)
26. Chen, C.M., H.C. Chou, L.F. Wang, et al. 2008. Captopril decreases plasminogen activator inhibitor-1 in rats with ventilatorinduced lung injury. Critical Care Medicine 36: 1880-1885.
27. Takahashi, H., S. Ebihara, T. Okazaki, et al. 2005. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparinase activity. British Journal of Pharmacology 146: 333-343. (Pubitemid 41486675)
28. Murakami, K., R. McGuire, R.A. Cox, et al. 2002. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18: 236-241.
29. Ogawa, Y., K. Yamakawa, H. Ogura, et al. 2012. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. Journal of Trauma and Acute Care Surgery 72: 1150-1157.
30. McMaken, S., M.C. Exline, P. Mehta, et al. 2011. Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS One 6: e19654.
31. Levi, Marcel, and Tom van der Poll. 2010. Inflammation and coagulation. Critical Care Medicine 38: S26-S34.
32. Krzyzaniak, M., G. Cheadle, C. Peterson, et al. 2011. Burn-induced acute lung injury requires a functional toll-like receptor 4. Shock 36: 24-29.
33. Wang, M., T. Liu, D. Wang, et al. 2011. Therapeutic effects of pyrrolidine dithiocarbamate on acute lung injury in rabbits. Journal of Translational Medicine 9: 61.
34. Wolfson, R.K., E.T. Chiang, and J.G. Garcia. 2011. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvascular Research 81: 189-197.
35. Ueno, H., T. Matsuda, S. Hashimoto, et al. 2004. Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine 170: 1310-1316. (Pubitemid 39657195)
36. Angus, D.C., L. Yang, L. Kong, et al. 2007. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Critical Care Medicine 35: 1061-1067. (Pubitemid 46598956)
37. Courtine, E., F. Pène, N. Cagnard, et al. 2011. Critical role of cRel subunit of NF-κB in sepsis survival. Infection and Immunity 79: 1848-1854.
38. Zingarelli, B. 2005. Nuclear factor-kappaB. Critical Care Medicine 33: S414-S416.
39. Kim, B.H., E. Roh, H.Y. Lee, et al. 2008. Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta. Molecular Pharmacology 73: 1309-1318. (Pubitemid 351439213)
40. Ha, T., Y. Xia, X. Liu, et al. 2011. Glucan phosphate attenuates myocardial HMGB1 translocation in severe sepsis through inhibiting NF-κB activation. American Journal of Physiology-Heart and Circulatory Physiology 301: H848-H855.
41. Esmon, C.T. 2001. Role of coagulation inhibitors in inflammation. Thrombosis and Haemostasis 86: 51-56. (Pubitemid 32663936)
42. Riewald, M., V.V. Kravchenko, R.J. Petrovan, et al. 2001. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 97: 3109-3116.
43. Skoutakis, V.A. 1997. Danaparoid in the prevention of thromboembolic complications. Annals of Pharmacotherapy 31: 876-887. (Pubitemid 27332480)
44. Kwak, H.J., J.S. Song, J.Y. Heo, et al. 2005. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38mitogen-activated protein kinase, and c- Jun NH2-terminal kinase activation. Journal of Pharmacology and Experimental Therapeutics 315: 1188-1195.
45. Schottelius, A.J., M.W. Mayo, R.B. Sartor, et al. 1999. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. Journal of Biological Chemistry 274: 31868-31874.
46. Cavaillon, J.M., C. Marie, M. Caroff, et al. 1996. CD14/LPS receptor exhibits lectin-like properties. Journal of Endotoxin Research 3: 471-480.
47. Anastase-Ravion, S., C. Blondin, B. Cholley, et al. 2003. Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. Journal of Biomedical Materials Research. Part A 66: 376-384. (Pubitemid 37517238)